A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Atridia Pty Ltd.

Criteria

Inclusion Criteria:

• Diagnosed (histologically or cytologically) with solid tumors

• ECOG Performance Status of 0 or 1 at both the screening and baseline visits

• Life expectancy ≥12 weeks

• Adequate laboratory parameters

• Willing and able to comply with clinic visits and study-related procedures

• Provide signed informed consent

Exclusion Criteria:

• Known history of hypersensitivity to the study drug

• Prior malignancy active within the previous 2 years

• Any investigational or concurrent cancer therapy

• History of immunodeficiency including seropositivity

• Systemic antibiotics treatment for ≥ 7 days before the first dose

• A known history of allogeneic organ transplantation